ArticleAntibiotics (Basel, Switzerland)2023
Prevalence and Associated Factors of
Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Prevalence and Antimicrobial Resistance Profiles of Enterococci Isolated From Humans, Animals, and Environment in Bangladesh: A Systematic Review and Meta-Analysis.International journal of microbiology · 2026Review
- Therapeutic effect of Bouea macrophylla Griffith in protecting Koi fish from Enterococcus faecalis infection and acute ammonia toxicity.Veterinary research communications · 2025Article
- Molecular Epidemiology and Genetic Context ofAntibiotics (Basel, Switzerland) · 2025Article
- Linezolid Resistance Genes and Mutations among Linezolid-SusceptibleAntibiotics (Basel, Switzerland) · 2024Article
- High prevalence and plasmidome diversity ofFrontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 8 institutions in 4 countries.
Funding
Abstract
Linezolid is an antibiotic of last resort for the treatment of infections caused by Gram-positive bacteria, including vancomycin-resistant enterococci.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.